DaVita’s Q2 Growth Slows, Yet Analysts Stick to 'Hold'

Forward-Looking Analysis

Market expectations for DaVita’s second quarter of 2026 indicate a deceleration in growth momentum. Analysts project revenue growth of 3.8% year-over-year, a notable slowdown from the 5% increase recorded in the same quarter last year. This revision suggests a more challenging operating environment compared to previous periods. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, indicating consensus that the business trajectory will remain stable heading into the report. DaVita has a historical tendency to rarely miss Wall Street’s revenue estimates, providing a baseline of predictability for the upcoming results.

Wall Street sentiment remains cautious, with a consensus "Hold" rating among eight covering analysts. The breakdown includes one sell, five holds, and two buy ratings. The average 12-month price target is set at $216.50, representing a forecasted downside of -9.31% from recent trading levels. Price targets vary significantly, ranging from a low of $140.00 to a high of $270.00. Recent analyst actions include two upgrades and one downgrade over the previous 90 days. Notably, Deutsche Bank upgraded its rating to "Buy" with a $220 target in May 2026, while UBS maintains a "Buy" rating with a higher $270 target. Conversely, BofA Securities retains a "Sell" rating with a $145 target. Despite positive sentiment in the broader healthcare providers sector, where share prices have risen an average of 6% over the last month, DaVita’s stock has remained largely unchanged, underscoring specific company-related headwinds or valuation concerns that analysts are pricing in.

Historical Performance Review

In the first quarter of 2026, DaVita delivered strong financial results, beating analyst expectations. The company reported revenues of $3.62 billion, marking a 9.9% year-over-year increase and a solid beat on revenue estimates. Net income reached $199.34 million, up 22.35% from the previous quarter and 35.4% year-over-year. Earnings per share stood at $2.58, reflecting a 28.55% quarterly increase and a 44.57% annual surge. These figures demonstrate robust profitability and successful execution against full-year guidance, setting a high bar for the subsequent quarter.

Additional News

DaVita has actively engaged in strategic and operational developments throughout 2026. On May 18, the company announced it set bold 2030 Community Care Commitments, following the successful exceedance of its prior five-year Environmental, Social, and Governance (ESG) goals. This highlights a continued focus on long-term sustainable healthcare practices. Earlier in May, DaVita confirmed its participation in the BofA Securities 2026 Health Care Conference, signaling ongoing investor relations efforts. On May 5, the company released its first-quarter 2026 financial results, which were subsequently discussed in an investor conference call scheduled for April 20. Additionally, on March 18, DaVita highlighted continued progress in value-based kidney care, noting that results from its Chronic Kidney Care Collaborative (CKCC) showed year-over-year improvement. These activities underscore the company's commitment to both clinical excellence and ESG standards as it navigates the current fiscal year.

Summary & Outlook

DaVita’s financial health remains solid, evidenced by strong Q1 2026 performance with significant year-over-year growth in revenue, net income, and EPS. However, the Q2 outlook presents a mixed picture. While the company has a history of beating estimates, projected revenue growth is slowing to 3.8%, suggesting potential margin pressures or volume challenges. The primary risk catalyst is the cautious Wall Street sentiment, reflected in a "Hold" consensus and a 9.31% downside in average price targets. Although recent upgrades from Deutsche Bank and UBS indicate some institutional confidence, the broader analyst community remains neutral. Consequently, the stance on future prospects is cautiously neutral; while operational fundamentals are strong, near-term valuation risks and decelerating growth metrics warrant careful monitoring until Q2 results clarify the trajectory.